1,059
Views
24
CrossRef citations to date
0
Altmetric
Original Articles

Hyperthermic isolated limb perfusion in locally advanced limb soft tissue sarcoma: A 24-year single-centre experience

, , , , &
Pages 165-172 | Received 05 Nov 2014, Accepted 24 Sep 2015, Published online: 25 Nov 2015

Figures & data

Table 1. Patient characteristics.

Table 2. Tumour response and local toxicity according to drug schedule.

Table 3. Local and systemic toxicity according to drug schedule in 117 sarcoma patients after hyperthermic isolated limb perfusion.

Figure 1. Flow chart of patient outcome. CR, complete response; CT, chemotherapy; HILP, hyperthermic isolated limb perfusion; L-PAM, melphalan; PR, partial response; R0, R1, R2, radicality of resection; RT, radiotherapy; SD, stable disease.

Figure 1. Flow chart of patient outcome. CR, complete response; CT, chemotherapy; HILP, hyperthermic isolated limb perfusion; L-PAM, melphalan; PR, partial response; R0, R1, R2, radicality of resection; RT, radiotherapy; SD, stable disease.

Figure 2. Local progression-free survival according to HILP drug schedule. HILP, hyperthermic isolated limb perfusion; L-PAM, melphalan; LPFS, local progression-free survival.

Figure 2. Local progression-free survival according to HILP drug schedule. HILP, hyperthermic isolated limb perfusion; L-PAM, melphalan; LPFS, local progression-free survival.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.